CORRECTION - Evident Acquired by Bain Capital: Partnership to Accelerate Future Growth and Innovation 4-04-2023, 01:28

Dave to Participate at Upcoming Investor Conferences 3-03-2023, 03:32

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26